||EPS - Basic
||Market Cap (m)
|Health Care Equipment & Services
Ekf Diagnostics Share Discussion Threads
Showing 1401 to 1422 of 1425 messages
|Lots of buys today; anyone speculate?|
|Hi All, I'm out of this one. Never thought a year ago I would be able to get out at north of 21p so absolutely delighted. Somehow made £3.5K on this share but on the whole it's not been an enjoyable journey and I have learned a lesson or two. So long and good luck!
|Square1...it will be interesting to see what the US open makes of the news (as I believe eyes from over there must be watching, especially given EKF's installed base of instruments).
Depending on how long things take and of course if it happens, in a low interest environment and in percentage terms, today's price and the buy back price offers of a potentially reasonable yield of circa 12%, especially so if things happen in quick fashion!|
|wan- they have clearly put themselves up for sale with offers above 21.5p IMO|
|I appreciate the directors currently hold a strong hand, but could today's news (and much improved Results) also provide the potential for a bid to emerge that values the company more in line with the value inflection and opportunity as that envisaged by splitting the company?|
|LOoks like end game . Company will leave AIM - expect PLUS market at best. AT least you can now get out at 21.5p. If I held I'd take that and not look back|
|7th Feb 2017
EKF's new Procalcitonin (PCT) study shows that testing reduces hospital costs and length of stay.
Sepsis carries a huge economic and human cost affecting over 27,000,000 people per year, and resulting in over 8,000,000 deaths per year 2. The USA spend over $20 billion dollars per year on sepsis care, so finding a way to screen and treat patients in the fastest, safest and most cost effective way is right at the top of many hospital agendas.
The EKF Diagnostics Procalcitonin LiquiColor® Test is a marker for bacterial infection and sepsis and can be used as a quick ten minute test, in conjunction with other tests, to quickly assess initial severity of sepsis. The test is CE marked and currently going through the FDA approval process. It is an open-channel test that can provide a cost effective solution for many hospital labs.
Full release - https://www.ekfdiagnostics.com/news.html|
|Well it looked like a very large 'cross' yesterday. (12m+)The amount on the buy side seems to equate to an amount that should be disclosed, so let's see. The price was below the then market too.|
|For the last couple of weeks there has been some relatively large individual trades reported (2m, 5m, 6m, 7m, 8m and 13m etc) all at the same price, so accordingly I would expect to see some holding announcements. If the Chairman has picked any of them up it could get quite interesting!|
|Some congratulations are in order. A good update|
|Does anyone have access to a recent brokers note on EKF? would appreciate a look.
Best regards SBP|
|Quite some turnaround at EKF, which looks set to continue with the current management making it happen!|
|Due for another tick up soon according to charts|
|Hi butchdogg nice to see you here, great company on the mend Flx is breaking out|
|this just popped up on a scan.. looks interesting. Hi Hamid i see you over on the FLX thread too.|
|Recent pound weakness post Brexit will be helping the figures as well. A bit of luck perhaps|
|Further to my post 1153 on 5th. October, I'm very pleased that the expected re-rating has come as soon as it has. Here's to the future ... :)|
|Business is booming that they had to revise expectations after 4 weeks again and all the growth is organic. Brilliant|
|NS Number : 4295OEKF Diagnostics Holdings PLC07 November 2016EKF Diagnostics Holdings plc("EKF", the "Company")Trading updateEKF Diagnostics Holdings plc (AIM: EKF), the AIM listed point-of-care business, announces that early trading in Q4 of the current financial year has again been materially higher than budget and at a run-rate in excess of already revised market forecasts, upgraded following the trading update provided on 7 October 2016.The Company now believes that it will achieve revenues of at least GBP36.5m and adjusted EBITDA for the year ending 31 December 2016 of at least GBP5.5m, therefore exceeding current market forecasts. The strong performance of the business is due to organic growth.In addition, the Company announces that cash generation continues to be strong and now expects to be close to breakeven if not cash positive by the year end, and then cash positive in the first quarter, again ahead of the board's previous expectations.|
|Wow that's a cracking update again|
|Still not sure how this business is worth £60m+ (even in a recovery phase). It feels like you are paying up for profits which may never materialise again... Even if it becomes cash positive, when will shareholders see REAL earnings?
Can anyone enlighten me?|
|Nice to see that this focused POC play is now yielding the benefits, with trading materially higher than budget and in excess of market forecasts.|